EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies

Justyna Jureczek iD, Krzysztof Kałwak, Piotr Dzięgiel

Cancers · 15.12.2024 · 16 (24) · 4181

DOI: 10.3390/cancers16244181 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.12.2024. Verfasst von Justyna Jureczek und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw,…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the great advancements in treatment strategies for hematological malignancies (HMs) over the years, their effective treatment remains challenging. Conventional treatment strategies are burdened with several serious drawbacks limiting their effectiveness and safety. Improved understanding of tumor immunobiology has provided novel anti-cancer strategies targeting selected immune response components. Currently, immunotherapy is counted as the fourth pillar of oncological treatment (together with surgery, chemo- and radiotherapy) and is becoming standard in the treatment regimen, alone or in combination therapy. Several categories of immunotherapies have been developed and are currently being assessed in clinical trials for the treatment of blood cancers, including immune checkpoint inhibitors, antigen-targeted antibodies, antibody–drug conjugates, tumor vaccines, and adoptive cell therapies. However, monoclonal antibodies (mAbs) and their derivatives have achieved the most notable clinical outcome so far. Since the approval of rituximab for treating B-cell malignancies, the availability of mAbs against tumor-specific surface molecules for clinical use has flourished. Antibody-based therapy has become one of the most successful strategies for immunotherapeutic cancer treatment in the last few decades, and many mAbs have already been introduced into standard treatment protocols for some hematologic malignancies. To further increase the efficacy of mAbs, they can be conjugated to radioisotopes or cytostatic drugs, so-called antibody–drug conjugates. Moreover, with the growing recognition of T-cell immunity’s role in cancer development, strategies aimed at enhancing T cell activation and inhibiting mechanisms that suppress T cell function are actively being developed. This review provides a comprehensive overview of the current status of immunotherapeutic strategies based on monoclonal antibodies and their derivatives, including antibody–drug conjugates, bispecific T-cell engagers, and checkpoint inhibitors, approved for the treatment of various HMs.

Schlagwörter

Stichwörter der Autor:innen

BiTeacute lymphoblastic leukemiacancerhematologic malignanciesimmunotherapylymphocytesmonoclonal antibodiesmultiple myelomarituximabtumor

Autor:innen und Institutionen

  • Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.
  • Clinical Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.

ORCID-Profile: Justyna Jureczek

Zitieren

APA

Jureczek, J., Kałwak, K., & Dzięgiel, P. (2024). Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies. Cancers, 16(24), 4181. https://doi.org/10.3390/cancers16244181

Vancouver

Jureczek J, Kałwak K, Dzięgiel P. Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies. Cancers. 2024;16(24):4181. doi:10.3390/cancers16244181

BibTeX
@article{Jureczek2024,
  author = {Jureczek, Justyna and Kałwak, Krzysztof and Dzięgiel, Piotr},
  title = {Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {24},
  pages = {4181},
  doi = {10.3390/cancers16244181}
}
Kostenlos starten →